What is "metelimumab"

n. A human monoclonal antibody intended for the treatment of scleroderma but later dropped in favour of alternatives.

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. Touted as a drug of the future, metelimumab was dropped from further development in favour of fresolimumab, which is currently being developed by Genzyme.